MOMENTUM: Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor

June 23, 2022 | Ruben Mesa, MD

Share on:

Ruben Mesa, MD, reviews the results from the MOMENTUM trial on momelotinib versus danazol in patients with myelofibrosis.

onclive rapid readouts logo